Rutin plus immunotherapy and chemo before bladder cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of the natural supplement rutin, an immunotherapy (tislelizumab), and two chemotherapy drugs (gemcitabine and cisplatin) before surgery for bladder cancer that didn't respond to initial chemo. It aims to see if this mix can shrink tumors better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your bladder cancer is muscle-invasive (stage T2-T4) and hasn't spread to lymph nodes or other organs.
- You've already had 2 cycles of chemotherapy with gemcitabine and cisplatin, and it didn't work.
- You haven't had immunotherapy or targeted therapy before.
- You are generally active and able to take care of yourself (ECOG score 0 or 1).
- You are at least 18 years old.
- You do not have severe heart, brain, liver, kidney problems, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.